Biotech drugmaker Amgen’s 3Q profit jumps 24 per cent on stronger sales of most of its drugs

TRENTON, N.J. – Biotech drugmaker Amgen Inc. says its third-quarter profit jumped 24 per cent and beat analysts’ expectations as sales of more than a half-dozen of its drugs increased by double digits.

Amgen, which sells arthritis treatment Enbrel and Prolia for osteoporosis, says net income was $1.37 billion, or $1.79 per share, up from $1.11 billion, or $1.41 per share, a year earlier.

The Thousand Oaks, Calif.-based company says earnings were $1.94 per share excluding one-time items. Analysts were expecting $1.76 per share.

Revenue was up 10 per cent at $4.75 billion. Analysts expected $4.6 billion.

The company also raised the lower end of its 2013 profit forecast by a nickel and now expects $7.35 to $7.45 per share.

News from © The Associated Press, . All rights reserved.
This material may not be published, broadcast, rewritten or redistributed.

The Associated Press

The Associated Press is an independent global news organization dedicated to factual reporting. Founded in 1846, AP today remains the most trusted source of fast, accurate, unbiased news in all formats and the essential provider of the technology and services vital to the news business. More than half the world’s population sees AP journalism every day.